Marktanalyse - Female Contraception - Pipeline Review, H2 2016

Global Markets Direct
12.2016
89 Seiten

 
Typ:
Marktanalyse
Verfüg­barkeit:
verfügbar
Regionen/­Länder:
  • Europa
  • Asien / Pazifik
  • Mittlerer Osten / Afrika
  • Nordamerika / USA
  • Australien
  • Mittel- / Südamerika
Sprache:
Englisch

Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:

PDF-Datei per E-Mail, Single User Price, versandkostenfrei
PDF-Datei per E-Mail, Site License Price**, versandkostenfrei
PDF-Datei per E-Mail, Enterprisewide Price (Global Site License)***, versandkostenfrei


Hinweise: **The report can be shared by users within one office (one geographical location) ***Across Geographical locations (by the purchasing company only)

Female Contraception - Pipeline Review, H2 2016


Summary


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Female Contraception — Pipeline Review, H2 2016, provides an overview of the Female Contraception (Women's Health) pipeline landscape.

Contraception (birth control) prevents pregnancy by interfering with the normal process of ovulation, fertilization, and implantation. There are many contraceptive methods which include implants and injections, intrauterine devices (IUDs), pills and vaginal rings, barrier methods, sterilization and natural methods. Contraception generally work by preventing sperm from reaching and fertilizing an egg (barrier and IUD methods), preventing an egg from being released every month (hormones), blocking the reproductive function (sterilization) and preventing a fertilized egg from implanting in the uterus (hormones).

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Female Contraception — Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Female Contraception (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Female Contraception (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Female Contraception and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 6, 5, 2, 6 and 5 respectively. Similarly, the Universities portfolio in Phase III and Preclinical stages comprises 1 and 2 molecules, respectively.

Female Contraception (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Female Contraception (Women's Health).
- The pipeline guide reviews pipeline therapeutics for Female Contraception (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Female Contraception (Women's Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Female Contraception (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Female Contraception (Women's Health)


Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Female Contraception (Women's Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Female Contraception (Women's Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Female Contraception Overview 9

Therapeutics Development 10

Pipeline Products for Female Contraception - Overview 10

Pipeline Products for Female Contraception - Comparative Analysis 11

Female Contraception - Therapeutics under Development by Companies 12

Female Contraception - Therapeutics under Investigation by Universities/Institutes 13

Female Contraception - Pipeline Products Glance 14

Late Stage Products 14

Clinical Stage Products 15

Early Stage Products 16

Female Contraception - Products under Development by Companies 17

Female Contraception - Products under Investigation by Universities/Institutes 19

Female Contraception - Companies Involved in Therapeutics Development 20

Addex Therapeutics Ltd 20

Agile Therapeutics Inc 21

ANI Pharmaceuticals Inc 22

Bayer AG 23

Evofem Inc 24

Hervana Ltd 25

Mithra Pharmaceuticals SA 26

Orbis Biosciences Inc 27

Teva Pharmaceutical Industries Ltd 28

Viramal Ltd 29

Female Contraception - Therapeutics Assessment 30

Assessment by Monotherapy Products 30

Assessment by Combination Products 31

Assessment by Target 32

Assessment by Mechanism of Action 34

Assessment by Route of Administration 36

Assessment by Molecule Type 38

Drug Profiles 40

(anastrozole + levonorgestrel) - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

(drospirenone + estetrol) - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

(estradiol acetate + prasterone + progesterone) - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

(estradiol acetate + segesterone acetate) - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

ADX-68693 - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

AG-200 ER - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

AG-200 SP - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

AG-20015 - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

AG-890 - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

Amphora - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

BAY-1007626 - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

drospirenone - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

Drug for Female Contraception - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

EC-508 - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

Estetrol - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

etonogestrel ER - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

EVE-106 - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

LJ-102 - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

Monoclonal Antibody Conjugates for Female Contraception - Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

NOV-1003 - Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

S-003296 - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

S-0101255 - Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

Small Molecule 2 for Fertility Control - Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

Small Molecule for Female Contraception - Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

Small Molecule to Target Progesterone Receptor for Female Contraception - Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

Small Molecule to Target Progesterone Receptor for Fertility Control - Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

Synthetic Peptides for Female Contraception - Drug Profile 75

Product Description 75

Mechanism Of Action 75

R&D Progress 75

TV-46046 - Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

Female Contraception - Dormant Projects 77

Female Contraception - Discontinued Products 79

Female Contraception - Product Development Milestones 80

Featured News & Press Releases 80

Nov 07, 2016: Agile Therapeutics Announces Completion of Subject Visits for Twirla Phase 3 SECURE Clinical Trial 80

Sep 23, 2016: Mithra Pharmaceuticals: Phase III Clinical Study for Estelle in US Launched with first Randomized Patient 80

Sep 20, 2016: Addex collaborators publish new data on negative allosteric modulator ADX68693 80

Jul 22, 2016: Green Light From FDA For The Launch Of Estelle (E4/Drsp) Phase III Study In The United States 81

Jul 20, 2016: Canada Approves Clinical Trial Application For Estelle (E4/DRSP) PhasePhase III Study 82

Jul 12, 2016: Agile Therapeutics Announces Plans to Advance Contraceptive Pipeline 82

Jun 30, 2016: First Patient Screened For The European Product Candidate Estelle (E4/Drsp) Phase III Clinical Study 83

Jun 16, 2016: Agile Therapeutics Announces Issuance of Patent for Progestin Patch Designs 83

Apr 05, 2016: FDA Feedback On Spa Estelle: A New Step Closer To The Launch Of Estelle Phase III Pivotal Clinical Studies 83

Apr 01, 2016: Topline Results Of Food Effect Study Of The Product Candidate Estelle, The New Combined Oral Contraceptive Composed Of 15 mg Of Estetrol (E4) And 3 mg Of Drospirenone 84

Mar 24, 2016: Already 4 European Countries Fully Approved Protocol Of MIT-ES001-C301 Estelle Phase III Clinical Study 84

Oct 19, 2015: Agile Therapeutics Announces Completion of Patient Enrollment in Twirla Phase 3 SECURE Clinical Trial 85

Oct 19, 2015: Agile Therapeutics Announces Completion of Patient Enrollment in Twirla Phase 3 SECURE Clinical Trial 85

Sep 22, 2015: Evofem Announces FDA Acceptance of New Drug Application for Amphora as a Contraceptive 86

Aug 31, 2015: Agile Therapeutics Announces Completion of Patient Recruitment in Twirla Phase 3 SECURE Clinical Trial 86

Appendix 88

Methodology 88

Coverage 88

Secondary Research 88

Primary Research 88

Expert Panel Validation 88

Contact Us 88

Disclaimer 89





List of Tables

Number of Products under Development for Female Contraception, H2 2016 10

Number of Products under Development for Female Contraception - Comparative Analysis, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Number of Products under Investigation by Universities/Institutes, H2 2016 13

Comparative Analysis by Late Stage Development, H2 2016 14

Comparative Analysis by Clinical Stage Development, H2 2016 15

Comparative Analysis by Early Stage Development, H2 2016 16

Products under Development by Companies, H2 2016 17

Products under Development by Companies, H2 2016 (Contd..1) 18

Products under Investigation by Universities/Institutes, H2 2016 19

Female Contraception - Pipeline by Addex Therapeutics Ltd, H2 2016 20

Female Contraception - Pipeline by Agile Therapeutics Inc, H2 2016 21

Female Contraception - Pipeline by ANI Pharmaceuticals Inc, H2 2016 22

Female Contraception - Pipeline by Bayer AG, H2 2016 23

Female Contraception - Pipeline by Evofem Inc, H2 2016 24

Female Contraception - Pipeline by Hervana Ltd, H2 2016 25

Female Contraception - Pipeline by Mithra Pharmaceuticals SA, H2 2016 26

Female Contraception - Pipeline by Orbis Biosciences Inc, H2 2016 27

Female Contraception - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2016 28

Female Contraception - Pipeline by Viramal Ltd, H2 2016 29

Assessment by Monotherapy Products, H2 2016 30

Assessment by Combination Products, H2 2016 31

Number of Products by Stage and Target, H2 2016 33

Number of Products by Stage and Mechanism of Action, H2 2016 35

Number of Products by Stage and Route of Administration, H2 2016 37

Number of Products by Stage and Molecule Type, H2 2016 39

Female Contraception - Dormant Projects, H2 2016 77

Female Contraception - Dormant Projects (Contd..1), H2 2016 78

Female Contraception - Discontinued Products, H2 2016 79





List of Figures

Number of Products under Development for Female Contraception, H2 2016 10

Number of Products under Development for Female Contraception - Comparative Analysis, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Number of Products under Investigation by Universities/Institutes, H2 2016 13

Comparative Analysis by Late Stage Development, H2 2016 14

Comparative Analysis by Clinical Stage Development, H2 2016 15

Comparative Analysis by Early Stage Products, H2 2016 16

Assessment by Monotherapy Products, H2 2016 30

Assessment by Combination Products, H2 2016 31

Number of Products by Targets, H2 2016 32

Number of Products by Stage and Targets, H2 2016 32

Number of Products by Top 10 Mechanism of Actions, H2 2016 34

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 34

Number of Products by Routes of Administration, H2 2016 36

Number of Products by Stage and Routes of Administration, H2 2016 36

Number of Products by Molecule Types, H2 2016 38

Number of Products by Stage and Molecule Types, H2 2016 38

* Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.

 

Über marktforschung.de

Branchenwissen an zentraler Stelle bündeln und abrufbar machen – das ist das Hauptanliegen von marktforschung.de. Unser breites Informationsangebot rund um die Marktforschung richtet sich sowohl an Marktforschungsinstitute, Felddienstleister, Panelbetreiber und Herausgeber von Studien, Marktdaten sowie Marktanalysen als auch an deren Kunden aus Industrie, Handel und Dienstleistungsgewerbe.

facebook twitter google plus